Tirzepatide vs Retatrutide: Dual vs Triple Agonist Comparison

Tirzepatide and retatrutide represent the current and next generation of multi-receptor weight loss peptides. Tirzepatide is the established option with regulatory approval and extensive clinical data. Retatrutide is the investigational frontier — producing the highest weight loss ever recorded in Phase 3 trials, but with less safety data and higher side effect rates. This comparison helps you weigh the trade-offs.

Tirzepatide activates two receptors: GLP-1 (appetite suppression, insulin) and GIP (enhanced metabolic effects, possible improved tolerability). This dual mechanism produces weight loss exceeding any single-target GLP-1 agonist.

Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The addition of glucagon receptor activation is the key differentiator — it increases hepatic energy expenditure, promotes fat burning in the liver, and stimulates thermogenesis. This effectively adds an energy output mechanism on top of the energy input reduction from GLP-1/GIP. The result is substantially greater weight loss.

Retatrutide produces dramatically more weight loss:

• Tirzepatide: ~20.9% average weight loss at 15 mg over 72 weeks (SURMOUNT-1)
• Retatrutide: ~28.7% average weight loss at 12 mg over 68 weeks (TRIUMPH-4 Phase 3)

Retatrutide also showed that 39.4% of participants lost 30% or more of their body weight — a result that approaches bariatric surgery outcomes. Tirzepatide's results, while impressive, do not reach this level.

However, retatrutide's Phase 3 data comes from a specific population (obesity with knee osteoarthritis). The broader TRIUMPH-1 trial (80 weeks, general obesity population) may show even greater weight loss when results are reported.

This is where tirzepatide has a clear advantage:

• Nausea: 31% (tirzepatide) vs 43% (retatrutide at 12 mg)
• Treatment discontinuation: 6.2% (tirzepatide) vs 18.2% (retatrutide at 12 mg)
• Novel signal: Retatrutide showed dose-dependent dysesthesia (abnormal touch sensations) in 20.9% of participants at 12 mg — a side effect not seen with tirzepatide or semaglutide

Retatrutide's higher side effect rates and the novel dysesthesia signal are trade-offs for its greater weight loss. The discontinuation rate of 18.2% is notably higher than tirzepatide's 6.2%, meaning nearly 1 in 5 people stopped treatment due to side effects.

Tirzepatide is available through select Bangkok clinics (branded pens) and peptide vendors (research-grade). Availability is limited compared to semaglutide but growing.

Retatrutide is only available as research-grade from peptide vendors. It is not offered at mainstream clinics. As an investigational compound, quality depends entirely on the vendor. There are no standardised compounding guidelines.

For most people in Thailand, tirzepatide is the more practical choice for access and reliability.

Choose tirzepatide if: - You want proven results backed by extensive Phase 3 data and regulatory approval - Tolerability matters to you (lower side effect rates) - You want a more established and accessible option in Thailand - You are getting started with dual-agonist therapy for the first time

Consider retatrutide if: - You have tried tirzepatide or semaglutide and want even greater results - Maximum weight loss is your primary goal and you accept higher side effect risk - You understand the investigational nature and limited long-term safety data - You are comfortable sourcing research-grade compounds from vendors

The progression for many users: Semaglutide → Tirzepatide → Retatrutide, moving to the next option if results plateau or are insufficient.